Scpharmaceutical Stock Price, News & Analysis

scPharmaceuticals (Nasdaq: SCPH) announced that CEO John Tucker will participate in two investor conferences: the Cowen 41st Annual Healthcare Conference on March 4 at 10:30 AM EDT and the H.C. Wainwright Global Life Sciences Conference from March 9 to March 10. A webcast of Tucker's presentation will be available on-demand starting March 9 at 7 AM ET. The company focuses on developing products that enhance the delivery of infused therapies and aims to reduce healthcare costs.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced on February 19, 2021, that it received FDA Type A meeting minutes regarding the FUROSCIX® NDA resubmission. No additional clinical efficacy or safety data is required, but the FDA seeks further bench testing and Pre-Approval Inspections. The company aims to resubmit the NDA in Q3 2021. As of December 31, 2020, scPharmaceuticals had approximately $105 million in cash, sufficient to fund operations into 2023. The ongoing Phase 3 FREEDOM trial evaluates FUROSCIX for heart failure patients.

scPharmaceuticals (Nasdaq: SCPH) announced the appointment of Dr. William T. Abraham to its Board of Directors. Dr. Abraham, an expert in heart failure, aims to enhance the company's focus on FUROSCIX®, a treatment for fluid overload in heart failure patients. CEO John Tucker expressed optimism about Dr. Abraham's contributions, as the company seeks regulatory approval for FUROSCIX® to address significant healthcare needs. The drug aims to provide outpatient treatment alternatives for patients showing reduced responsiveness to oral diuretics.

scPharmaceuticals Inc. (Nasdaq: SCPH) announced that CEO John Tucker will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24 at 11:20 EDT. The company focuses on optimizing infused therapies to enhance patient care and reduce healthcare costs, particularly for heart failure and infectious diseases. A live webcast of the presentation will be available on their website. For more details, visit scpharmaceuticals.com.

scPharmaceuticals Inc. (SCPH) announced on December 3, 2020, that it received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application for FUROSCIX®. The CRL cited the need for pre-approval inspections at third-party manufacturing facilities that could not be conducted due to travel restrictions. Additionally, the FDA raised questions about testing, labeling, and other features of the product. The company will request a Type A meeting with the FDA to address these issues. As of Q3, scPharmaceuticals reported cash holdings sufficient to fund operations into 2023.

BURLINGTON, Mass., Nov. 19, 2020 – scPharmaceuticals (Nasdaq: SCPH) announced that John Tucker, the president and CEO, will present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on December 3 at 11:20 AM EST. This presentation highlights the company's focus on optimizing infused therapies and reducing healthcare costs. A live webcast of the presentation will be available on the company's Investor Relations website.

scPharmaceuticals is dedicated to developing innovative products aimed at improving health outcomes, particularly in outpatient care for heart failure and infectious diseases.

scPharmaceuticals Inc. (Nasdaq: SCPH) continues preparations for the December 30 PDUFA date for FUROSCIX®, with ongoing commercialization activities and submission of 12-month drug stability data to the FDA. The company has enrolled the first patient in the FREEDOM-HF Phase 3 trial, aimed at evaluating the cost-effectiveness of FUROSCIX in heart failure patients. Financially, scPharmaceuticals reported a net loss of $9.0 million for Q3 2020, with total cash reserves of $114.5 million, and revised its projected 2020 net loss to $34-37 million.

scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company dedicated to enhancing patient care and reducing healthcare costs, announced that CEO John Tucker will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:35 EDT / 5:35 GMT. The presentation will provide insights into the company's ongoing efforts to develop innovative therapies that facilitate outpatient care for acute conditions. A live webcast will be available on the company's website under the Investor Relations section.

scPharmaceuticals Inc. (Nasdaq: SCPH) provided a business update on FUROSCIX^®, its investigational formulation of furosemide intended for subcutaneous administration. The FDA has set a PDUFA date for December 30, 2020. The company has expanded its commercial team and submitted twelve-month drug stability data to the FDA. Recent presentations at the Heart Failure Society of America meeting highlighted FUROSCIX's potential as a cost-effective treatment for heart failure congestion. The company emphasized its commitment to addressing significant unmet medical needs in this area.